Author:
Jones Alan,Peers Katherine,Wierzbicki Anthony S.,Ramachandran Radha,Mansfield Michael,Dawson Charlotte,Ochoa-Ferraro Antonio,Soran Handrean,Jenkinson Fiona,McDowell Ian,Downie Paul,Hamilton Paul,Jones Richard D
Subject
Cardiology and Cardiovascular Medicine
Reference13 articles.
1. Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia;Gaudet;Eur. Heart J.,2020
2. The burden of familial chylomicronemia syndrome: results from the global IN-FOCUS study;Davidson;J Clin Lipidol,2018
3. Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement;Hegele;Lancet Diabetes Endocrinol.,2020
4. Clinical and biochemical features of different molecular etiologies of familial chylomicronemia;Hegele;J Clin Lipidol,2018
5. Characterizing familial chylomicronemia syndrome: baseline data of the APPROACH study;Blom;J Clin Lipidol,2018
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献